$IBRX
ImmunityBio, Inc. Stock $ibrx

$ibrx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000132611022000074 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$73.00K	$118.0K	$66.00K
YoY Change	-81.28%	78.79%	-56.29%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$26.22M	$19.31M	$29.63M
YoY Change	-6.08%	-34.82%	51.18%
% of Gross Profit
Research & Development	$57.58M	$71.61M	$49.28M
YoY Change	11.25%	45.33%	37.75%
% of Gross Profit
Depreciation & Amortization	$5.226M	$4.100M	$3.687M
YoY Change	45.37%	11.2%	53.63%
% of Gross Profit
Operating Expenses	$84.29M	$90.92M	$78.90M
YoY Change	5.81%	15.23%	19.5%
Operating Profit		-$90.80M	-$78.84M
YoY Change		15.18%	19.67%
Interest Expense	-$22.50M	$16.76M	$3.614M
YoY Change	100.68%	363.86%	62.35%
% of Operating Profit
Other Income/Expense, Net	-$896.0K	-$20.36M	-$9.593M
YoY Change	238.11%	112.21%	381.33%
Pretax Income	-$108.3M	-$111.2M	-$88.43M
YoY Change	18.28%	25.71%	30.29%
Income Tax	$34.00K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$108.2M	-$110.9M	-$87.63M
YoY Change	18.58%	26.6%	33.57%
Net Earnings / Revenue	-148239.73%	-94015.25%	-132771.21%
Basic Earnings Per Share		-$0.28	-$0.22
Diluted Earnings Per Share	-$0.27	-$0.28	-$0.22
COMMON SHARES
Basic Shares Outstanding	400.3M shares	400.3M shares	391.9M shares
Diluted Shares Outstanding		400.1M shares	391.9M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$107.2M	$111.1M	$80.37M
YoY Change	-66.2%	38.18%	-44.97%
Cash & Equivalents	$104.6M	$104.2M	$64.52M
Short-Term Investments	$2.543M	$6.896M	$15.85M
Other Short-Term Assets	$3.732M	$3.236M	$255.0K
YoY Change	-32.82%	1169.02%	183.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$1.890M
Total Short-Term Assets	$140.6M	$143.1M	$94.45M
YoY Change	-57.95%	51.5%	-3.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$143.7M	$130.4M	$69.88M
YoY Change	73.37%	86.67%	25.09%
Goodwill
YoY Change
Intangibles	$20.00M	$20.47M	$1.432M
YoY Change	1308.66%	1329.54%
Long-Term Investments	$840.0K	$811.0K	$802.0K
YoY Change	2.19%	1.12%	-91.98%
Other Assets	$4.860M	$5.133M	$7.442M
YoY Change	-28.27%	-31.03%	266.78%
Total Long-Term Assets	$221.8M	$209.9M	$120.0M
YoY Change	64.81%	74.92%	45.39%
TOTAL ASSETS
Total Short-Term Assets	$140.6M	$143.1M	$94.45M
Total Long-Term Assets	$221.8M	$209.9M	$120.0M
Total Assets	$362.4M	$352.9M	$214.4M
YoY Change	-22.72%	64.6%	18.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.02M	$20.24M	$15.12M
YoY Change	84.06%	33.84%	145.45%
Accrued Expenses	$41.83M	$46.22M	$38.52M
YoY Change	-18.61%	19.99%	600.73%
Deferred Revenue
YoY Change
Short-Term Debt	$431.9M	$0.00	$0.00
YoY Change	44.33%
Long-Term Debt Due	$4.886M	$5.479M	$12.83M
YoY Change	23.92%	-57.31%
Total Short-Term Liabilities	$500.9M	$70.84M	$65.41M
YoY Change	35.74%	8.3%	216.55%
LONG-TERM LIABILITIES
Long-Term Debt	$241.3M	$661.1M	$303.2M
YoY Change	-21.22%	118.02%
Other Long-Term Liabilities	$457.0K	$569.0K	$905.0K
YoY Change	83.53%	-37.13%	-91.99%
Total Long-Term Liabilities	$457.0K	$569.0K	$905.0K
YoY Change	83.53%	-37.13%	-91.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$500.9M	$70.84M	$65.41M
Total Long-Term Liabilities	$457.0K	$569.0K	$905.0K
Total Liabilities	$812.2M	$782.0M	$404.4M
YoY Change	13.94%	93.4%	1167.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.400B	-$2.300B	-$1.900B
YoY Change	22.33%	21.05%	163.01%
Common Stock	$1.931B	$1.844B	$1.682B
YoY Change	12.28%	9.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$447.3M	-$426.7M	-$188.5M
YoY Change
Total Liabilities & Shareholders Equity	$362.4M	$352.9M	$214.4M
YoY Change	-22.72%	64.6%	18.79%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$108.2M	-$110.9M	-$87.63M
YoY Change	18.58%	26.6%	33.57%
Depreciation, Depletion And Amortization	$5.226M	$4.100M	$3.687M
YoY Change	45.37%	11.2%	53.63%
Cash From Operating Activities	-$90.73M	-$80.60M	-$72.72M
YoY Change	26.64%	10.84%	297.79%
INVESTING ACTIVITIES
Capital Expenditures	$18.93M	-$15.93M	-$8.032M
YoY Change	-281.98%	98.39%	372.47%
Acquisitions
YoY Change
Other Investing Activities	$37.00K	$14.77M	$18.61M
YoY Change	-100.03%	-20.67%	-134.12%
Cash From Investing Activities	-$18.89M	-$1.168M	$10.58M
YoY Change	-86.29%	-111.04%	-118.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	109.9M	124.0M	42.66M
YoY Change	-66.27%	190.66%	-8805.31%
NET CHANGE
Cash From Operating Activities	-90.73M	-80.60M	-72.72M
Cash From Investing Activities	-18.89M	-1.168M	10.58M
Cash From Financing Activities	109.9M	124.0M	42.66M
Net Change In Cash	319.0K	42.22M	-19.48M
YoY Change	-99.73%	-316.75%	-74.04%
FREE CASH FLOW
Cash From Operating Activities	-$90.73M	-$80.60M	-$72.72M
Capital Expenditures	$18.93M	-$15.93M	-$8.032M
Free Cash Flow	-$109.7M	-$64.67M	-$64.68M
YoY Change	79.07%	-0.03%	290.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001326110
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q3	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37507
	dei	Entity Registrant Name EntityRegistrantName	IMMUNITYBIO, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	43-1979754
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3530 John Hopkins Court
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	633-0300
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	IBRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	400304106	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104161000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181101000	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	6896000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	136015000	usd
CY2022Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1488000	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1333000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	30547000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15898000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	143092000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	334347000	usd
CY2022Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	811000	usd
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	822000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	130441000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	82863000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20471000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1420000	usd
CY2022Q3	ibrx	Convertible Note Receivable Non Current ConvertibleNoteReceivableNonCurrent	6566000	usd
CY2021Q4	ibrx	Convertible Note Receivable Non Current ConvertibleNoteReceivableNonCurrent	6379000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46429000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36304000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5133000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6775000	usd
CY2022Q3	us-gaap	Assets Assets	352943000	usd
CY2021Q4	us-gaap	Assets Assets	468910000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	20237000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11418000	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	46220000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	51387000	usd
CY2022Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	3018000	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	3943000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1365000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3011000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	70840000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	368995000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	49561000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	37068000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	569000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	411000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	782024000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	712823000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	400304106	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	400304106	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	397830044	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	397830044	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	163800	shares
CY2022Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	163800	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	40000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	40000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1843724000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1719704000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2270273000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1961921000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-190000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-426699000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-242173000	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-2382000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-1740000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-429081000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-243913000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	352943000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	468910000	usd
CY2022Q3	us-gaap	Revenues Revenues	118000	usd
CY2021Q3	us-gaap	Revenues Revenues	66000	usd
	us-gaap	Revenues Revenues	167000	usd
	us-gaap	Revenues Revenues	544000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	71612000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49277000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	190072000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	144205000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19310000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29625000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	76493000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	107345000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	90922000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	78902000	usd
	us-gaap	Operating Expenses OperatingExpenses	266565000	usd
	us-gaap	Operating Expenses OperatingExpenses	251550000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-90804000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-78836000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-266398000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-251006000	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	857000	usd
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-5941000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	723000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	2826000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	16764000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	3614000	usd
	us-gaap	Interest Expense InterestExpense	34953000	usd
	us-gaap	Interest Expense InterestExpense	10359000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4456000	usd
CY2021Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8553000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	187000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	252000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-20357000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9593000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-42596000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7281000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-111161000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88429000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-308994000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-258287000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-111161000	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-88429000	usd
	us-gaap	Profit Loss ProfitLoss	-308994000	usd
	us-gaap	Profit Loss ProfitLoss	-258295000	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-223000	usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-800000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-642000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2764000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-110938000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-87629000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-308352000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-255531000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.77
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	400059707	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	400059707	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	391853623	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	391853623	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	398652562	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	398652562	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	386606200	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	386606200	shares
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-111161000	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-88429000	usd
	us-gaap	Profit Loss ProfitLoss	-308994000	usd
	us-gaap	Profit Loss ProfitLoss	-258295000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-22000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-1000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-183000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	16000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-119000	usd
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-58000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	17000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-130000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-85000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-80000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	16000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-194000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-69000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-111241000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-88413000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-309188000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-258364000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-223000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-800000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-642000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-2764000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-111018000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-87613000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-308546000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-255600000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-243913000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10024000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	74000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	372000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-371000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-102998000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-337556000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10175000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	15000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	257000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-94835000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-421974000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10630000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	10000	usd
CY2022Q3	ibrx	Stock Issued During Period Value Litigation Settlement StockIssuedDuringPeriodValueLitigationSettlement	10656000	usd
CY2022Q3	ibrx	Adjustments To Additional Paid In Capital Gain Loss On Extinguishment Of Debt With Related Party AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty	82858000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-80000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-111161000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-429081000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-118490000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15298000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1121000	usd
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2624000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-160000	usd
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-80481000	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-185336000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	94887000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17863000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3311000	usd
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	75000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-89385000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-158585000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	42061000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13840000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	678000	usd
CY2021Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	960000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	1435000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	16000	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-88429000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-189944000	usd
	us-gaap	Profit Loss ProfitLoss	-308994000	usd
	us-gaap	Profit Loss ProfitLoss	-258295000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	30829000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	47001000	usd
	ibrx	Non Cash Interest Income Expense From Operating Activities NonCashInterestIncomeExpenseFromOperatingActivities	-13770000	usd
	ibrx	Non Cash Interest Income Expense From Operating Activities NonCashInterestIncomeExpenseFromOperatingActivities	-9126000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13034000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10643000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4280000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3500000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1318000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-261000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	681000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	162000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	2383000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-127000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-307000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14420000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-425000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2138000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4844000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	7563000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-170000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	7253000	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	624000	usd
	ibrx	Increase Decrease In Due To Related Parties Current And Non Current IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent	-1639000	usd
	ibrx	Increase Decrease In Due To Related Parties Current And Non Current IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent	-4714000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2306000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3647000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-246782000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-202780000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59231000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23160000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	21229000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	20498000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	34293000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2749000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	128188000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	44759000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	33756000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	13568000	usd
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1000000	usd
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	46191000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	52916000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	136948000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	124375000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	40000000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	74000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5110000	usd
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	usd
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	1435000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	397000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64524000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3584000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	40000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	339000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	419000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	123673000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	179490000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	123000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-17000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-76795000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29609000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	181280000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	35094000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	104485000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	64703000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104161000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	324000	usd
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	179000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	104485000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	64703000	usd
	us-gaap	Interest Paid Net InterestPaidNet	21000000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1466000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	11000	usd
	ibrx	Adjustments To Additional Paid In Capital Gain Loss On Extinguishment Of Debt With Related Party AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty	82858000	usd
	ibrx	Adjustments To Additional Paid In Capital Gain Loss On Extinguishment Of Debt With Related Party AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13787000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	19461000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12469000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5582000	usd
	us-gaap	Stock Issued1 StockIssued1	10656000	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	199000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-64000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	16000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these notes to unaudited condensed consolidated financial statements, the terms “ImmunityBio,” “the company,” “the combined company,” “we,” “us,” and “our” refer to ImmunityBio and subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ImmunityBio, Inc. is a clinical-stage biotechnology company developing next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. We strive to be a vertically-integrated immunotherapy company designing and manufacturing our products so they are more effective, accessible, more conveniently stored, and more easily administered to patients. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad immunotherapy and cell therapy platforms are designed to attack cancer and infectious pathogens by activating both the innate immune system—natural killer (NK) cells, dendritic cells, and macrophages—and the adaptive immune system—B cells and T cells—in an orchestrated manner. The goal of this potentially best-in-class approach is to generate immunogenic cell death thereby eliminating rogue cells from the body whether they are cancerous or virally infected. Our ultimate goal is to employ this approach to establish an “immunological memory” that confers long-term benefit for the patient. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although such designations may not lead to a faster development process or regulatory review and may not increase the likelihood that a product candidate will receive approval, Anktiva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (N-803), our novel antibody cytokine fusion protein, has received </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designations in combination with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bacillus Calmette-Guérin (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCG) from the United States (U.S.) Food and Drug Administration (FDA) for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> BCG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. I</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022, we announced the submission of a Biologics License Application (BLA) to the FDA for our product candidate, Anktiva in combination with BCG for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without Ta or T1 disease. In July 2022, we announced the FDA has accepted our BLA for review and set a target Prescription Drug User Fee Act (PDUFA) action date of May 23, 2023. It is unclear when the FDA will approve our BLA, if at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platforms include 9 first-in-human therapeutic agents that are currently being studied in 27 clinical trials—17 of which are in Phase 2 or 3 development—across 13 indications in liquid and solid tumors, including bladder, pancreatic, and lung cancers. These are among the most frequent and lethal cancer types for which there are high failure rates for existing standards of care or, in some cases, no available effective treatment. In infectious disease, our pipeline currently targets such pathogens as the novel strain of the coronavirus (SARS-CoV-2) and human immunodeficiency virus (HIV). </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established Good Manufacturing Practice (GMP) manufacturing capacity at scale with cutting-edge cell manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned research and development (R&D), clinical trial, and regulatory operations, and development teams.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Merger</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 21, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NantKwest, Inc. (NantKwest) and NantCell, Inc. (formerly known as ImmunityBio, Inc., a private company) (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NantCell)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered into an Agreement and Plan of Merger (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), pursuant to which NantKwest and NantCell agreed to combine their businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merger</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), with NantCell surviving the Merger as a wholly-owned subsidiary of the company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 9, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective Time),</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each share of NantCell common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, par value $0.001 per share, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive 0.8190 (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange Ratio)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> newly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued shares of common stock, par value $0.0001 per share, of the company (Company Common Stock), with cash paid in lieu of any fractional shares.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the Effective Time, each share of the company’s common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, RSU or warrant to purchase NantCell common stock was converted using the Exchange Ratio into an option, RSU or warrant, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the Effective Time, the former stockholders of NantCell held approximately 71.5% of the outstanding shares of Company Common Stock and the stockholders of NantKwest as of immediately prior to the Merger held approximately 28.5% of the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr. Patrick Soon-Shiong, our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Chairman and Global Chief Scientific and Medical Officer,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and his affiliates beneficially owned, in the aggregate, approximately 81.8% of the outstanding shares of Company Common Stock. Following the consummation of the Merger, the symbol for shares of the company’s common stock was changed to “IBRX.”</span></div>
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2300000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-246800000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, asset acquisition, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</span></div>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17926704	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12908670	shares
CY2022Q3	ibrx	Prepaid Services PrepaidServices	14069000	usd
CY2021Q4	ibrx	Prepaid Services PrepaidServices	6966000	usd
CY2022Q3	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	5000000	usd
CY2021Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	0	usd
CY2022Q3	ibrx	Insurance Premium Financing Asset InsurancePremiumFinancingAsset	2461000	usd
CY2021Q4	ibrx	Insurance Premium Financing Asset InsurancePremiumFinancingAsset	2598000	usd
CY2022Q3	us-gaap	Supplies Supplies	2160000	usd
CY2021Q4	us-gaap	Supplies Supplies	0	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	1870000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2266000	usd
CY2022Q3	ibrx	Prepaid Software License Fees PrepaidSoftwareLicenseFees	1751000	usd
CY2021Q4	ibrx	Prepaid Software License Fees PrepaidSoftwareLicenseFees	1111000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	3236000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2957000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	30547000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15898000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	195043000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	135937000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	64602000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	53074000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	130441000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	82863000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	4100000	usd
CY2021Q3	us-gaap	Depreciation Depreciation	3700000	usd
	us-gaap	Depreciation Depreciation	11700000	usd
	us-gaap	Depreciation Depreciation	10600000	usd
CY2022Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	8744000	usd
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	8316000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7399000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6909000	usd
CY2022Q3	ibrx	Accrued Construction Costs Current AccruedConstructionCostsCurrent	7340000	usd
CY2021Q4	ibrx	Accrued Construction Costs Current AccruedConstructionCostsCurrent	8145000	usd
CY2022Q3	ibrx	Accrued Preclinical And Clinical Trial Costs AccruedPreclinicalAndClinicalTrialCosts	5775000	usd
CY2021Q4	ibrx	Accrued Preclinical And Clinical Trial Costs AccruedPreclinicalAndClinicalTrialCosts	5842000	usd
CY2022Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5414000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5613000	usd
CY2022Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	5000000	usd
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	7118000	usd
CY2022Q3	ibrx	Financing Obligation Current FinancingObligationCurrent	2461000	usd
CY2021Q4	ibrx	Financing Obligation Current FinancingObligationCurrent	2598000	usd
CY2022Q3	ibrx	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	2204000	usd
CY2021Q4	ibrx	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	2107000	usd
CY2022Q3	ibrx	Accrued Laboratory Equipment Supplies And Related Services AccruedLaboratoryEquipmentSuppliesAndRelatedServices	338000	usd
CY2021Q4	ibrx	Accrued Laboratory Equipment Supplies And Related Services AccruedLaboratoryEquipmentSuppliesAndRelatedServices	2144000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1545000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2595000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46220000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51387000	usd
CY2022Q3	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	614000	usd
CY2021Q3	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-6008000	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	162000	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	2383000	usd
CY2022Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	253000	usd
CY2021Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	101000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	2193000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	552000	usd
CY2022Q3	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-10000	usd
CY2021Q3	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-34000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-1513000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-282000	usd
CY2022Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2021Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-119000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	173000	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	857000	usd
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-5941000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	723000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	2826000	usd
CY2022Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	12240000	usd
CY2021Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	3593000	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	29660000	usd
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	10307000	usd
CY2022Q3	ibrx	Amortization Of Debt Discount Premium Related Party AmortizationOfDebtDiscountPremiumRelatedParty	4498000	usd
CY2021Q3	ibrx	Amortization Of Debt Discount Premium Related Party AmortizationOfDebtDiscountPremiumRelatedParty	0	usd
	ibrx	Amortization Of Debt Discount Premium Related Party AmortizationOfDebtDiscountPremiumRelatedParty	5242000	usd
	ibrx	Amortization Of Debt Discount Premium Related Party AmortizationOfDebtDiscountPremiumRelatedParty	0	usd
CY2022Q3	us-gaap	Interest Expense Other InterestExpenseOther	26000	usd
CY2021Q3	us-gaap	Interest Expense Other InterestExpenseOther	21000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	51000	usd
	us-gaap	Interest Expense Other InterestExpenseOther	52000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	16764000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	3614000	usd
	us-gaap	Interest Expense InterestExpense	34953000	usd
	us-gaap	Interest Expense InterestExpense	10359000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	932000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	94000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	847000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	130060000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	116000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	37000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	130139000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	13	security
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	0	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	0	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	846000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	94000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	86273000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	37000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	147000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46429000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36304000	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	154000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0	usd
CY2022Q3	ibrx	Lease Right Of Use Asset LeaseRightOfUseAsset	46583000	usd
CY2021Q4	ibrx	Lease Right Of Use Asset LeaseRightOfUseAsset	36304000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1365000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3011000	usd
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	75000	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	49561000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	37068000	usd
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	84000	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2022Q3	ibrx	Lease Liability LeaseLiability	51085000	usd
CY2021Q4	ibrx	Lease Liability LeaseLiability	40079000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y9M18D
CY2022Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096
CY2022Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.117
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2841000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1546000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	8091000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	5410000	usd
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2086000	usd
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2086000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2022Q3	ibrx	Finance Lease Costs Right Of Use Asset Amortization And Interest Expense FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense	56000	usd
CY2021Q3	ibrx	Finance Lease Costs Right Of Use Asset Amortization And Interest Expense FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense	0	usd
	ibrx	Finance Lease Costs Right Of Use Asset Amortization And Interest Expense FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense	56000	usd
	ibrx	Finance Lease Costs Right Of Use Asset Amortization And Interest Expense FinanceLeaseCostsRightOfUseAssetAmortizationAndInterestExpense	0	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	808000	usd
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	856000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	2924000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	2039000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	5791000	usd
CY2021Q3	us-gaap	Lease Cost LeaseCost	2402000	usd
	us-gaap	Lease Cost LeaseCost	13157000	usd
	us-gaap	Lease Cost LeaseCost	7449000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	7350000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	5878000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	40000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	11000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	0	usd
	ibrx	Operating Lease Payments Related To Options To Extend Lease Terms OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms	14800000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2632000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	22000	usd
CY2022Q3	ibrx	Lease Liability To Be Paid Remainder Of Fiscal Year LeaseLiabilityToBePaidRemainderOfFiscalYear	2654000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9534000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	88000	usd
CY2022Q3	ibrx	Lease Liability To Be Paid Year One LeaseLiabilityToBePaidYearOne	9622000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	12112000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	66000	usd
CY2022Q3	ibrx	Lease Liability To Be Paid Year Two LeaseLiabilityToBePaidYearTwo	12178000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12151000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0	usd
CY2022Q3	ibrx	Lease Liability To Be Paid Year Three LeaseLiabilityToBePaidYearThree	12151000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10289000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	usd
CY2022Q3	ibrx	Lease Liability To Be Paid Year Four LeaseLiabilityToBePaidYearFour	10289000	usd
CY2022Q3	ibrx	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	31457000	usd
CY2022Q3	ibrx	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	0	usd
CY2022Q3	ibrx	Lease Liability To Be Paid After Year Four LeaseLiabilityToBePaidAfterYearFour	31457000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	78175000	usd
CY2022Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	176000	usd
CY2022Q3	ibrx	Lease Liability To Be Paid LeaseLiabilityToBePaid	78351000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	23362000	usd
CY2022Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	17000	usd
CY2022Q3	ibrx	Lease Liability Undiscounted Excess Interest LeaseLiabilityUndiscountedExcessInterest	23379000	usd
CY2022Q3	ibrx	Lessee Operating Lease Liability Tenant Improvement Allowance Receivable LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable	3887000	usd
CY2022Q3	ibrx	Finance Lease Liability Tenant Improvement Allowance Receivable FinanceLeaseLiabilityTenantImprovementAllowanceReceivable	0	usd
CY2022Q3	ibrx	Lease Liability Tenant Improvement Allowance Receivable LeaseLiabilityTenantImprovementAllowanceReceivable	3887000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	50926000	usd
CY2022Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	159000	usd
CY2022Q3	ibrx	Lease Liability LeaseLiability	51085000	usd
CY2022Q3	ibrx	Adjustments To Additional Paid In Capital Gain Loss On Extinguishment Of Debt With Related Party AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty	82900000	usd
	ibrx	Adjustments To Additional Paid In Capital Gain Loss On Extinguishment Of Debt With Related Party AdjustmentsToAdditionalPaidInCapitalGainLossOnExtinguishmentOfDebtWithRelatedParty	82900000	usd
CY2022Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4200000	usd
CY2022Q3	ibrx	Related Party Notes Payable RelatedPartyNotesPayable	701644000	usd
CY2022Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	39090000	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	79680000	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	661054000	usd
CY2021Q4	ibrx	Related Party Notes Payable RelatedPartyNotesPayable	576644000	usd
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	30379000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1438000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	605585000	usd
CY2022Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1488000	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1333000	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3018000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3943000	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10630000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13840000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30829000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	47001000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10630000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13840000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30829000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	47001000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4124930	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.62
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4178000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5736256	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.33
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	14767	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.07
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	506242	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.95
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9340177	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.84
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4655000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3463222	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	14.70
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	2650000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4728634	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.83
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3038322	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001326110-22-000074-index-headers.html	Edgar Link	pending
0001326110-22-000074-index.html	Edgar Link	pending
0001326110-22-000074.txt	Edgar Link	pending
0001326110-22-000074-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ibrx-20220930.htm	Edgar Link	pending
ibrx-20220930.xsd	Edgar Link	pending
ibrx-20220930x10qexhibit101.htm	Edgar Link	pending
ibrx-20220930x10qexhibit102.htm	Edgar Link	pending
ibrx-20220930x10qexhibit103.htm	Edgar Link	pending
ibrx-20220930x10qexhibit104.htm	Edgar Link	pending
ibrx-20220930x10qexhibit105.htm	Edgar Link	pending
ibrx-20220930x10qexhibit106.htm	Edgar Link	pending
ibrx-20220930x10qexhibit107.htm	Edgar Link	pending
ibrx-20220930x10qexhibit108.htm	Edgar Link	pending
ibrx-20220930x10qexhibit311.htm	Edgar Link	pending
ibrx-20220930x10qexhibit312.htm	Edgar Link	pending
ibrx-20220930x10qexhibit321.htm	Edgar Link	pending
ibrx-20220930x10qexhibit322.htm	Edgar Link	pending
ibrx-20220930_g1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
ibrx-20220930_cal.xml	Edgar Link	unprocessable
ibrx-20220930_def.xml	Edgar Link	unprocessable
ibrx-20220930_pre.xml	Edgar Link	unprocessable
ibrx-20220930_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ibrx-20220930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBRX
ImmunityBio, Inc. Stock $ibrx

2022 Q4 Form 10-Q Financial Statement

#000132611022000074 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBRX ImmunityBio, Inc. Stock $ibrx

2022 Q4 Form 10-Q Financial Statement

#000132611022000074 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBRX
ImmunityBio, Inc. Stock $ibrx